Summit Therapeutics SMMT
NASDAQ SMMT
$16.40 +0.92 (+5.94%)
As of: Sep 29, 2026 · 3:59 PM EDT

Summit Therapeutics (SMMT) Non-Current Debt (2022 - 2024)

Updated

Summit Therapeutics' Non-Current Debt came in at $100 million for Q1 2024, unchanged from $100 million a year earlier and unchanged from the prior quarter.

Analysis

Summit Therapeutics (SMMT) Non-Current Debt (2022 - 2024) Analysis & Trends

Going back to Q1 2022, Summit Therapeutics' Non-Current Debt data covers 7 quarters.

  • Going back by year, Non-Current Debt was $494.54 million in FY2022.
  • The five-year range for quarterly Non-Current Debt is $25.06 million (Q1 2022) to $494.54 million (Q4 2022).
  • Year-over-year, Non-Current Debt increased in two of the last four quarters, with growth averaging 128.6%.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 37.34 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 62.48 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 51.08 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -108.00 Mn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 51.86 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 23.83 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 60.50 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Summit Therapeutics 12.28 Bn 10.04 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 100.00 Mn
Dec 31, 2023 100.00 Mn
Jun 30, 2023 100.00 Mn
Mar 31, 2023 100.00 Mn
Dec 31, 2022 494.54 Mn
Jun 30, 2022 25.31 Mn
Mar 31, 2022 25.06 Mn
API Access

Summit Therapeutics Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=SMMT&period=max&api_key=YOUR_API_KEY